Steven Y. Hua

1.6k citations

37 papers · 1.2k indexed · 1 hit paper · h-index 16

Genetics top 10%
Immunology top 10%
Oncology top 10%
Epidemiology
Radiology, Nuclear Medicine and Imaging top 10%

Co-authors: Silvio Danese Geert D’Haens Douglas C. Wolf William J. Sandborn Brian G. Feagan Subrata Ghosh Loren Laine Ji Hwan Lee
Topics: Monoclonal and Polyclonal Antibodies Research (9 papers)Biosimilars and Bioanalytical Methods (8 papers)Pharmaceutical studies and practices (7 papers)
Cited by: Immunology Genetics Rheumatology
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States Canada United Kingdom

In The Last Decade

Steven Y. Hua

37 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

2021 335 citations William J. Sandborn, Brian G. Feagan et al. profile →

Peers

Countries citing papers authored by Steven Y. Hua

Since Specialization

Citations

This map shows the geographic impact of Steven Y. Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Y. Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Y. Hua more than expected).

Fields of papers citing papers by Steven Y. Hua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Y. Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Y. Hua. The network helps show where Steven Y. Hua may publish in the future.

Co-authorship network of co-authors of Steven Y. Hua

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Y. Hua. A scholar is included among the top collaborators of Steven Y. Hua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Y. Hua. Steven Y. Hua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Global, regional, and national burden of ischemic stroke in older adults (≥60 years) from 1990 to 2021 and projections to 2030 2025 ·Frontiers in Neurology ·Steven Y. Hua,Zhiyong Dong,Hui Wang,Tong Liu	1
2	POS1128 ZETOMIPZOMIB (KZR-616) TREATMENT RESULTS IN CLINICALLY MEANINGFUL RENAL RESPONSES IN PATIENTS WITH LUPUS NEPHRITIS 2023 ·Annals of the Rheumatic Diseases ·Amit Saxena,Samir V. Parikh,Steven Y. Hua,(unknown),(unknown),Noreen Henig	3
3	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study 2020 ·The Lancet. Gastroenterology & hepatology ·Brian G. Feagan,William J. Sandborn,Silvio Danese,Douglas C. Wolf,(unknown),Steven Y. Hua,Neil Minton,Allan Olson,Geert D’Haens	107
4	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis 2020 ·Clinical Gastroenterology and Hepatology ·Evan S. Dellon,Margaret H. Collins,Marc E. Rothenberg,Yehudith Assouline-Dayan,Larry Evans,Sandeep K. Gupta,Alain Schoepfer,Alex Straumann,Ekaterina Safroneeva,(unknown),Neil Minton,Steven Y. Hua,Ikuo Hirano	61
5	An anti–IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results 2020 ·Journal of Allergy and Clinical Immunology ·Peter H. Gann,Ryan Deaton,(unknown),Margaret H. Collins,Evan S. Dellon,Ikuo Hirano,Steven Y. Hua,(unknown),Sarah Harris	37
6	A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors 2019 ·Investigational New Drugs ·Lee S. Rosen,Robert Wesolowski,Raffaele Baffa,(unknown),Steven Y. Hua,(unknown),Steven Pirie‐Shepherd,Anthony W. Tolcher	41
7	P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial 2019 ·Journal of Crohn s and Colitis ·Brian G. Feagan,William J. Sandborn,Geert D’Haens,Stephen B. Hanauer,Douglas C. Wolf,Séverine Vermeire,Subrata Ghosh,(unknown),Steven Y. Hua,(unknown),(unknown)	2
8	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy 2018 ·Arthritis Research & Therapy ·Stanley Cohen,Rieke Alten,Hideto Kameda,Tomas Hala,S. Radominski,(unknown),(unknown),Karl Schumacher,Susanne Schmitt,Steven Y. Hua,(unknown),K. Lea Sewell	45
9	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis 2018 ·Arthritis Research & Therapy ·Roy Fleischmann,Rieke Alten,Margarita Pileckytė,Kasia Lobello,Steven Y. Hua,Carol Cronenberger,Daniel Alvarez,(unknown),K. Lea Sewell	42
10	A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors 2018 ·Investigational New Drugs ·Gentry Teng King,Keith D. Eaton,(unknown),(unknown),Gilbert Y. Wong,Heike I. Krupka,Steven Y. Hua,Wells A. Messersmith,Anthony B. El-Khoueiry	68
11	First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors 2017 ·Investigational New Drugs ·Geoffrey I. Shapiro,Ulka N. Vaishampayan,Patricia LoRusso,Jeremy Barton,Steven Y. Hua,Steven D. Reich,Ronald Shazer,Carrie Turich Taylor,Dawei Xuan,Hossein Borghaei	32
12	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab 2013 ·Journal of Clinical Oncology ·Luis Fayad,Fritz Offner,Mitchell R. Smith,Gregor Verhoef,Peter Johnson,Jonathan L. Kaufman,A. Z. S. Rohatiner,Anjali S. Advani,James M. Foran,Georg Heß,Bertrand Coiffier,Myron S. Czuczman,Eva Giné,Simon Durrant,Michelle Kneissl,Kenneth T. Luu,Steven Y. Hua,Joseph Boni,Erik Vandendries,Nam H. Dang	119
13	Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma 2010 ·Ghent University Academic Bibliography (Ghent University) ·Gregor Verhoef,(unknown),Mitchell R. Smith,(unknown),Peter Johnson,A. Z. S. Rohatiner,(unknown),Eva Giné,B Coiffier,M. S. Czuczman,James M. Foran,Simon Durrant,Steven Y. Hua,Erik Vandendries,Joseph Boni,Luis Fayad	2
14	Multivariate Failure Time Analysis when only the Time to First Failure is Observed 2010 ·Communications in Statistics - Simulation and Computation ·Steven Y. Hua,D.L. Hawkins,(unknown),Ying‐Qi Zhao	1
15	Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5% 2008 ·Ophthalmology ·Martin B. Kaback,Stephen V. Scoper,(unknown),(unknown),Steven Y. Hua,(unknown),Jaime E. Dickerson,Theresa Landry,Michael V.W. Bergamini	38
16	Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial 2008 ·Journal of American Association for Pediatric Ophthalmology and Strabismus ·Jess T. Whitson,John D. Roarty,Lingam Vijaya,Alan L. Robin,Robert D. Gross,Theresa Landry,Jaime E. Dickerson,(unknown),(unknown),Steven Y. Hua,(unknown),Michael V.W. Bergamini	21
17	Travoprost 0.004% With and Without Benzalkonium Chloride: A Comparison of Safety and Efficacy 2007 ·Journal of Glaucoma ·(unknown),Martin J. Weiss,(unknown),(unknown),Jack E. James,Steven Y. Hua,(unknown),(unknown),David T. Wells,Michael V.W. Bergamini,(unknown)	1
18	The effect of contact lens induced oedema on the accuracy of Goldmann tonometry in a mature population 2007 ·British Journal of Ophthalmology ·(unknown),David Pye,Steven Y. Hua,Fei Yu,Jae-Wook Chung,Qiang Hou	15
19	Comparison of the Safety and IOP–Lowering Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination to the Concomitant Administration of Xalatan® and Timolol 0.5% 2006 ·Investigative Ophthalmology & Visual Science ·J Henry,(unknown),(unknown),David T. Wells,Steven Y. Hua,Theresa Landry,Michael V.W. Bergamini,(unknown)	2
20	Activity of an Alcohol-Based Hand Gel Against Human Adeno-, Rhino-, and Rotaviruses Using the Fingerpad Method 2000 ·Infection Control and Hospital Epidemiology ·Syed A. Sattar,(unknown),(unknown),Hanuman B. Jampani,Jerry Newman,Steven Y. Hua	82

About Steven Y. Hua

Steven Y. Hua is a scholar working on Statistics and Probability, Aging and Radiology, Nuclear Medicine and Imaging, having authored 37 papers that have together received 1.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (9 papers), Biosimilars and Bioanalytical Methods (8 papers) and Pharmaceutical studies and practices (7 papers). The work is most often cited by research in Immunology (305 citations), Genetics (336 citations) and Rheumatology (174 citations). Steven Y. Hua has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Silvio Danese, Geert D’Haens, Douglas C. Wolf, William J. Sandborn, Brian G. Feagan, Subrata Ghosh, Loren Laine, Ji Hwan Lee, Keith Usiskin and AnnKatrin Petersen. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact